Bean-Based Gum Offers Promising Strategy Against Influenza and Herpes, Study Finds
In an era where global connectivity heightens the risk of widespread disease transmission, viral infections such as COVID-19, H1N1, SARS, Ebola, Zika, and avian influenza (H5N1) have shown just how disruptive and dangerous infectious diseases can be—not only to public health but also to the world economy.
Yet, even more common viruses like seasonal influenza and herpes simplex virus-1 (HSV-1) contribute significantly to global disease burden. In the U.S. alone, flu outbreaks result in over $11.2 billion in annual losses, while HSV-1 infects nearly 67% of the global population, making it the leading infectious cause of blindness in Western nations.
Despite the threat, flu vaccination rates remain low, and no vaccine currently exists for HSV. This has led scientists to explore innovative alternatives that target viral transmission directly at its source—especially the mouth, a key site for viral spread in both HSV and influenza infections.
A new study published in Molecular Therapy introduces one such breakthrough: an antiviral chewing gum made from lablab beans (Lablab purpureus). Developed by researchers at the University of Pennsylvania School of Dental Medicine, in collaboration with Finnish partners, the gum uses a naturally occurring antiviral protein called FRIL (found in the beans) to bind and neutralize virus particles.
Led by Dr. Henry Daniell, W.D. Miller Professor at Penn Dental Medicine, the research team tested the gum’s ability to trap and neutralize herpes simplex viruses (HSV-1, HSV-2) and influenza A strains (H1N1 and H3N2). Their findings showed that a 40-milligram dose within a two-gram gum tablet was enough to reduce viral loads by over 95%—comparable to their previous success in lowering SARS-CoV-2 levels in saliva.
What sets this work apart is not just the gum’s effectiveness, but also its safety and FDA-compliant preparation as a clinical-grade product. This opens the door to real-world applications and broader clinical trials.
The team is now expanding the use of bean powder for avian flu control, especially as the H5N1 strain continues to wreak havoc across North America, infecting 54 million birds in just three months, with multiple human cases also reported in the U.S. and Canada.
Earlier studies had already suggested that lablab bean proteins could neutralize bird flu strains like H5N1 and H7N9. Now, Dr. Daniell’s team is exploring the possibility of incorporating bean powder into poultry feed to help mitigate the spread of these viruses among birds.
“Virus control remains one of the world’s most pressing health issues,” says Dr. Daniell. “A natural antiviral like FRIL, derived from a food-safe plant, offers a powerful and versatile tool—not only for flu and herpes in humans, but also for combating avian flu outbreaks. It’s a timely solution to a global challenge.”
This research represents a promising step forward in preventing virus transmission through natural, affordable, and scalable methods.
